In NSCLC, trials have shown that patients with EGFR mutant tumors do not benefit from PD-1 or PD-L1 inhibitors.48, 49 Further studies have demonstrated that EGFR mutant and ALK-rearrangement-positive NSCLC tumors lacked concurrent CD8+ T cell infiltration and PD-L1 expression, which is associated with inferior efficacy of PD-1 or PD-L1 inhibitors in this subset of the population.50 This evidence concerns the gene CD274 and non-small cell lung carcinoma.